ITRM Iterum Therapeutics

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced it will participate in the 2024 Maxim Healthcare Virtual Summit. Corey Fishman, CEO of Iterum, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 10:00 a.m. ET on October 16, 2024.

The Maxim Healthcare Summit will take place from October 15 – 17, 2024. This conference will be live on M-Vest. To access, register and watch the fireside chat here: .

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has submitted an NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit .

Investor Contact:

Judy Matthews 

Chief Financial Officer

312-778-6073



EN
09/10/2024

Underlying

ITRMIterum Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iterum Therapeutics

 PRESS RELEASE
Free
ITRM Iterum Therapeu...

Iterum Therapeutics Reports Second Quarter 2025 Financial Results

Iterum Therapeutics Reports Second Quarter 2025 Financial Results -- Launch of ORLYNVAHTM Expected August 2025— --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2025. "We are on track to launch ORLYNVAH™ this month for th...

August 5, 2025 1 EN
 PRESS RELEASE
Free
ITRM Iterum Therapeu...

Iterum Therapeutics to Report Second Quarter 2025 Financial Results on...

Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 DUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, August 5, 2025. Management will host a conference call at 8:30 a.m. ET that ...

July 29, 2025 1 EN
 PRESS RELEASE
Free
ITRM Iterum Therapeu...

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule...

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum’s newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducemen...

July 2, 2025 1 EN
 PRESS RELEASE
Free
ITRM Iterum Therapeu...

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYN...

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the Un...

June 30, 2025 1 EN
 PRESS RELEASE
Free
ITRM Iterum Therapeu...

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Ev...

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence 9.2% of Patients in REASSURE’s Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that NEJM Evidence published results from its REASSURE (REnewed ASsessment of Sul...

June 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch